InMed Pharmaceuticals (INM) Cash from Operations (2019 - 2026)

InMed Pharmaceuticals has reported Cash from Operations for 8 years, with the latest figure at 1695136.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 2.15% year-over-year to 1695136.0; the trailing twelve-month figure through Mar 2026 stood at 7457501.0 (down 6.27% YoY), and the FY2025 full-year result was 7766951.0, down 11.18% from the prior year.
• Cash from Operations for Q1 2026 stood at 1695136.0, up from 2376243.0 in the prior quarter.
• The five-year high for Cash from Operations was 657934.0 in Q2 2023, with the low at 5348786.0 in Q1 2022.
• Historically, Cash from Operations has averaged 2183000.59 across 5 years, with a median of 1848133.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 101.75% — and 2023, when it surged 83.74%.
• InMed Pharmaceuticals' Cash from Operations stood at 2713096.0 in 2022, then jumped by 31.88% to 1848133.0 in 2023, then plunged by 35.39% to 2502138.0 in 2024, then climbed by 5.03% to 2376243.0 in 2025, then grew by 28.66% to 1695136.0 in 2026.
• The last three Cash from Operations figures came in at 1695136.0 (Q1 2026), 2376243.0 (Q4 2025), and 1607616.0 (Q3 2025), per Business Quant data.